Nilsson Kent R, Berenholtz Sean M, Dorman Todd, Garrett Elizabeth, Lipsett Pamela, Kaufman Howard S, Pronovost Peter J
Department of Anesthesiology/CCM, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-7294, USA.
J Gastrointest Surg. 2002 Sep-Oct;6(5):753-62. doi: 10.1016/s1091-255x(02)00043-4.
Transfusion is associated with multiple risks and morbidities. Little is known, however, about preoperative predictors of transfusion in gastrointestinal surgery patients. To identify factors that influence transfusion practices, we analyzed hospital discharge data from colorectal cancer surgery patients in Maryland between 1994 and 2000 (n = 14,052). The primary outcome variable was whether or not patients received a blood product ("Any Transfusion"). Characteristics independently associated with an increased risk of receiving Any Transfusion included: advanced age (>80 yr: OR 2.3; 95% CI 1.9-2.9; 70-79 yr: OR 1.6; 95% CI 1.4-2.0 vs. <60 yr), moderate to severe liver disease (OR 2.5; 95% CI 1.5-4.2), mild liver disease (OR 2.1; 95% CI 1.5-2.9), diabetes with complications (OR 2.1; 95% CI 1.6-2.6), chronic renal disease (OR 2.1; 95% CI 1.4-3.0), female gender (OR 1.3; 95% CI 1.2-1.5), chronic pulmonary disease (COPD) (OR 1.3; 95% CI 1.1-1.4), and metastatic disease (OR 1.2; 95% CI 1.1-1.4). Patients at hospitals with an annual case volume in the highest quartile were at an increased risk for receiving Any Transfusion (OR 2.1; 95% CI 1.3-3.4) and those with surgeons in the highest volume quartile (>12 cases/yr) were at a decreased risk (OR 0.8; 95% CI 0.6-0.99). The association between greater surgeon case volume and low transfusion rates was seen in all but the very high volume hospitals (>74 cases/yr). Blood product transfusion was associated with a 2.5-fold (95% CI 2.1-3.1) increased mortality, 3.7 day (95% CI 2.1-3.1) increase in hospital length of stay, and a 7120 dollars (95% CI 6472 dollars-7769 dollars) increase in total charges compared to patients that did not receive Any Transfusion. This data can be used by providers in discussions with patients regarding the risks for transfusion and in identifying patients in whom strategies to reduce transfusions should be evaluated.
输血与多种风险及发病率相关。然而,对于胃肠外科手术患者术前输血的预测因素却知之甚少。为了确定影响输血行为的因素,我们分析了1994年至2000年间马里兰州结直肠癌手术患者的医院出院数据(n = 14,052)。主要结局变量是患者是否接受了血液制品(“任何输血”)。与接受任何输血风险增加独立相关的特征包括:高龄(>80岁:比值比2.3;95%置信区间1.9 - 2.9;70 - 79岁:比值比1.6;95%置信区间1.4 - 2.0,对比<60岁)、中度至重度肝病(比值比2.5;95%置信区间1.5 - 4.2)、轻度肝病(比值比2.1;95%置信区间1.5 - 2.9)、伴有并发症的糖尿病(比值比2.1;95%置信区间1.6 - 2.6)、慢性肾病(比值比2.1;95%置信区间1.4 - 3.0)、女性(比值比1.3;95%置信区间1.2 - 1.5)、慢性肺病(慢性阻塞性肺疾病,COPD)(比值比1.3;95%置信区间1.1 - 1.4)以及转移性疾病(比值比1.2;95%置信区间1.1 - 1.4)。年病例量处于最高四分位数的医院的患者接受任何输血的风险增加(比值比2.1;95%置信区间1.3 - 3.4),而外科医生年手术量处于最高四分位数(>12例/年)的患者风险降低(比值比0.8;95%置信区间0.6 - 0.99)。除了手术量非常高的医院(>74例/年)外,在所有医院中都观察到外科医生手术量越大与输血率越低之间的关联。与未接受任何输血的患者相比,血液制品输血与死亡率增加2.5倍(95%置信区间2.1 - 3.1)、住院时间延长3.7天(95%置信区间2.1 - 3.1)以及总费用增加7120美元(95%置信区间6472美元 - 7769美元)相关。这些数据可供医疗服务提供者在与患者讨论输血风险以及确定应评估减少输血策略的患者时使用。